Ardea seeks $144.5M in public offering as it advances PhIII oral gout drug
This article was originally published in Scrip
Executive Summary
Ardea BioSciences, a biotech focused on small molecule therapeutics for serious diseases is seeking $144.5 million before expenses from a public offering of 8.5 million shares at $17 per share, a 7% discount to its closing price on 1 February when the company proposed the offering..